There is disclosed compositions and methods relating to or derived from anti-cd38 antibodies. More specifically, there is disclosed fully human antibodies that bind cd38, cd38-antibody binding fragments and derivatives of such antibodies, and cd38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...

The present invention relates to anti-her2 binding molecules (e. G., antibodies and antigen binding fragments thereof), derived her2-binding molecules (e. G., bispecific anti-her2 antibodies), and antibody-drug conjugates (adc) that bind the extracellular domain of the her2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with her2-mediated signal transduction.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

There is disclosed compositions and methods relating to or derived from anti-cd123 antibodies. More specifically, there is disclosed fully human antibodies that bind cd123, cd123-antibody binding fragments and derivatives of such antibodies, and cd123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...

A novel method to reduce b-cell lymphoma cell migration to and engraftment of the spleen in patients with jam-c positive b-cell lymphomas is described. In certain aspects, a method for identifying and treating jam-c positive b-cell lymphoma patients with anti-jam-c antibodies is provided. Recombinant antibody molecules that specifically bind to jam-c are also disclosed.

The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hifnγ), thereby modulating the interaction between ifnγ and its receptor, ifnγ-r, and/or modulating the biological activities of ifnγ. The invention also relates to the use of such anti-ifnγ antibodies in the prevention ...

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, ...

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a and a peptide tag that binds hyaluronan (ha). The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17...

The present invention relates to discovery of the ectopic expression of edem2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the cho cell, containing recombinant polynucleotides encoding edem2. Also disclosed is a production cell containing both an edem2...

The invention provides anti-cd22 antibodies and immunoconjugates and methods of using the same.

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey lag3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e. G., including anti-pd1 antibodies) are included ...

An anti-il-23 antibody, including isolated nucleic acids that encode at least one anti-il-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from ccr4-igg1 and recognizes the same epitope. This antibody contains either an igg4 or a stabilized igg4 in order to improve binding efficiency and reduce in vivo fab arm exchange. Binding of the antibodies ...

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i. E., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e. G., a canine), the ...

Uses of apo2l/trail polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.

The present invention is based, in part, on the discovery of peptide tags that increase the half-life and/or mean residence time of proteins or nucleic acids in the eye. In certain aspects the invention peptide tags increase the half-life and/or mean residence time of antibodies and antigen binding fragments, therapeutic proteins, protein receptors, darpins and/or aptamers in ...

Provided is an improved method for detecting antibodies to a hepatitis virus in a tissue sample from individuals, which can reliably detect antibodies in recently infected individuals and which provides much lower false positive results in individuals that have cleared their hepatitis infections. Further provided is an improved method and kit which utilizes an activator of (i) hepatitis virus-primed lymphocytes, (...

Portable devices for anti-drug antibodies (adas) testing are provided. These devices can be used in various applications, including but not restricted to the following: uniform testing of patients for adas; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs ...

The present invention provides methods of treating alport syndrome in a subject by the administration of an agent that blocks the activation of rac1/cdc42 members of the rho family of small gtpases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of ...

The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v ...

The amino acid and nucleic acid sequences of a Δ5-desaturase enzyme and a Δ8-desaturase enzyme are disclosed. The nucleic acid sequences can be used to design recombinant dna constructs and vectors. These vectors can then be used to transform various organisms, including for example, plants and yeast. The transformed organisms will then produce polyunsaturated fatty acids. The amino ...